Pneumococcal immunisation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:14:57 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pneumococcal immunisation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of 20-valent pneumococcal conjugate vaccine (PCV20) booster response in healthy adults aged 78-84 years https://clinicaltrials.eu/trial/study-of-20-valent-pneumococcal-conjugate-vaccine-pcv20-booster-response-in-healthy-adults-aged-78-84-years/ Wed, 29 Apr 2026 15:07:29 +0000 https://clinicaltrials.eu/trial/study-of-20-valent-pneumococcal-conjugate-vaccine-pcv20-booster-response-in-healthy-adults-aged-78-84-years/ This clinical trial aims to study immune responses to Prevenar 20, a vaccine that helps prevent pneumococcal infection. The vaccine contains 20 different types of pneumococcal bacteria and is given as an injection into the muscle. The study focuses on healthy adults between 78 and 84 years old who previously received a different pneumococcal vaccine called PPSV23 in 2020.

The study will evaluate how well the immune system responds to Prevenar 20 when given as a booster vaccination. Participants will receive a single 0.5 milliliter dose of the vaccine. Blood samples will be collected before vaccination, one month after, and eleven months after to measure the body’s immune response to the vaccine.

The research will also examine immune responses in the mucous membranes, which are the body’s natural protective barriers. These measurements will help determine how effectively the vaccine stimulates both general and localized immunity against pneumococcal bacteria, which can cause serious infections like pneumonia.

]]> Study on the Safety and Immune Response of a 21-Valent Pneumococcal Vaccine in Healthy Infants, Toddlers, Children, and Adolescents https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-a-21-valent-pneumococcal-vaccine-in-healthy-infants-toddlers-children-and-adolescents/ Wed, 29 Apr 2026 15:05:52 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-a-21-valent-pneumococcal-vaccine-in-healthy-infants-toddlers-children-and-adolescents/ This clinical trial is focused on studying the effects of a new vaccine called Pneumococcal Conjugate Vaccine (PCV21) in healthy infants, toddlers, children, and adolescents. The vaccine is designed to protect against infections caused by the bacteria Streptococcus pneumoniae, which can lead to serious illnesses such as pneumonia, meningitis, and bloodstream infections. The study will compare the new 21-valent vaccine, which targets 21 different types of the bacteria, with an existing 20-valent vaccine known as PREVNAR 20®.

The purpose of the study is to evaluate the safety and immune response of the new vaccine. Participants will receive the vaccine through an injection into the muscle. The study will monitor the participants for any immediate reactions, as well as any other side effects that may occur after receiving the vaccine. The immune response will be measured by checking the levels of specific antibodies, which are proteins in the blood that help fight infections, 30 days after the last dose of the vaccine.

The study will involve several visits over a period of time to ensure the safety and effectiveness of the vaccine. Participants will be observed for any adverse events, which are any unwanted effects that occur after receiving the vaccine. The study aims to provide valuable information on how well the new vaccine works in different age groups and its potential to offer broader protection against pneumococcal diseases.

]]> Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-a-21-valent-pneumococcal-conjugate-vaccine-in-healthy-infants-and-toddlers/ Wed, 29 Apr 2026 15:05:33 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-a-21-valent-pneumococcal-conjugate-vaccine-in-healthy-infants-and-toddlers/ This clinical trial is focused on studying a vaccine for preventing infections caused by the bacteria *Streptococcus pneumoniae*, commonly known as pneumococcal disease. This disease can lead to serious infections like pneumonia, meningitis, and bloodstream infections, especially in young children. The study will compare two vaccines: a new 21-valent *Pneumococcal Conjugate Vaccine (PCV21)* and an existing 15-valent vaccine called *Vaxneuvance*. The term “valent” refers to the number of different types of bacteria the vaccine can protect against. The purpose of the study is to see if the new vaccine is as effective or better than the existing one in producing a strong immune response in infants and toddlers.

Participants in the study will receive either the new *PCV21* vaccine or the *Vaxneuvance* vaccine. The vaccines are given as a series of injections into the muscle. The study will monitor the immune response by measuring the levels of antibodies, which are proteins the body makes to fight infections. The study will also check for any side effects or reactions to the vaccines. The goal is to ensure that the new vaccine is safe and effective for young children.

The study will last for several months, with follow-up visits to check the health and immune response of the participants. The researchers will look at how well the vaccines work against the different types of pneumococcal bacteria included in the vaccines. This information will help determine if the new vaccine can provide better protection against pneumococcal disease in children. The study will also track any immediate or long-term side effects to ensure the safety of the vaccines.

]]> Study on Pneumococcal Vaccine Response in Healthy Volunteers Using Pneumococcal Polysaccharide Conjugate Vaccine and Drug Combination https://clinicaltrials.eu/trial/study-on-pneumococcal-vaccine-response-in-healthy-volunteers-using-pneumococcal-polysaccharide-conjugate-vaccine-and-drug-combination/ Wed, 29 Apr 2026 15:05:29 +0000 https://clinicaltrials.eu/trial/study-on-pneumococcal-vaccine-response-in-healthy-volunteers-using-pneumococcal-polysaccharide-conjugate-vaccine-and-drug-combination/ This clinical trial is focused on studying the body’s immune response to the pneumococcal vaccine. Pneumococcal disease is caused by bacteria that can lead to serious infections like pneumonia, meningitis, and bloodstream infections. The study involves two vaccines: Apexxnar, a 20-valent pneumococcal polysaccharide conjugate vaccine, and Prevenar 13, a 13-valent pneumococcal polysaccharide conjugate vaccine. Both vaccines are designed to protect against different strains of the bacteria that cause pneumococcal disease.

The purpose of the study is to understand how the immune system, particularly the lymph nodes, responds to these vaccines. Lymph nodes are small glands that play a crucial role in the body’s defense against infections. The study will look at the timing of the peak response of certain immune cells, known as B cells, in the lymph nodes after vaccination. It will also examine other immune cells, such as T cells, and various markers that indicate how the immune system is reacting.

Participants in the study will receive one of the vaccines and will have samples taken from their lymph nodes and blood at different times. These samples will help researchers understand the changes in immune cells and the levels of cytokines, which are substances that help regulate the immune response. The study aims to provide insights into how well the vaccines work in stimulating the immune system to protect against pneumococcal disease.

]]>